TIM3 blockade with hypomethylating therapy restores NK and cytotoxic CD4+ T cell activity in patients with AML or MDS
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Occasional complete responses to immune checkpoint inhibitor therapies suggest that acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are immune-sensitive when appropriately targeted. Here, we analyzed AML/MDS patients treated with anti-TIM3 sabatolimab and decitabine in a phase Ib clinical trial ( NCT03066648 ) using single-cell RNA and T cell receptor (TCR) sequencing and functional co-culture assays. Unlike T cell restricted CTLA4 and PD1, TIM3 was broadly expressed across natural killer (NK), myeloid, and T cell populations. Therapy induced expansion of cytotoxic NK cell subsets and enhanced type I interferon signaling. Less than 1% of bone marrow CD8+ T cells showed canonical exhaustion phenotypes, and the treatment preferably expanded small CD8+ T cell clones in responders. Responders had more cytotoxic CD4+ T and B cells which was exemplified by a patient with an outstanding complete response of 23-months. Over >20% of this patient's lymphocytes were CD4+ T-cell large granular lymphocyte leukemia (T-LGLL) cells that expressed a TCR capable of recognizing autologous blasts.
